Takeda Emerging Markets Sales Drop

BMI View: Takeda will continue to underperform its rivals over the medium term. Sales, net income and earnings per share (EPS) all declined in the most recent financial reporting period. The company has a small and contracting presence in emerging markets. Most significantly, Takeda is facing the full spectrum of growth headwinds for the pharmaceutical industry.

To read the full article, please choose one of the following options: